

October 17, 2018

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated October 17, 2018 titled "Zydus receives final approval from the USFDA for Clobetasol Propionate Cream".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

for, 
UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Clobetasol Propionate Cream

Ahmedabad, 17 October, 2018

Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Cream, (US RLD – Temovate® Cream), 0.05%. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Clobetasol Propionate is a topical (for the skin) steroid used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

The group now has 222 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
